

HETEROCYCLES, Vol. 74, 2007, pp. 553 - 568. © The Japan Institute of Heterocyclic Chemistry  
Received, 18th August, 2007, Accepted, 5th October, 2007, Published online, 12th October, 2007. COM-07-S(W)34


# SYNTHESES OF AMIDE-SUBSTITUTED ISOXAZOLES AND PYRAZOLES VIA REGIOSELECTIVE [3 + 2] CYCLOADDITIONS OF TERMINALLY UNSUBSTITUTED YNAMIDES†

Hongyan Li, Lingfeng You, Xuejun Zhang, Whitney L. Johnson, Ruth Figueroa, and Richard P. Hsung\*

Division of Pharmaceutical Sciences and Department of Chemistry,  
777 Highland Avenue, University of Wisconsin, Madison, WI 53705 U.S.A  
rhsung@wisc.edu

† This paper is dedicated to Professor Ekkehard Winterfeldt with the deepest respect on the special occasion of his 75th birthday.

**Abstract** – A series of regioselective [3 + 2] cycloadditions of terminally unsubstituted ynamides with nitrile oxides and ethyl  $\alpha$ -diazoacetate is described here. These reactions provide an excellent synthetic entry to *de novo* 5-amide-substituted isoxazoles via a Cu(I)-catalyzed pathway and 3-amide-substituted pyrazoles via a thermally driven cycloaddition.




## INTRODUCTION


The 1,3-dipolar cycloaddition reaction<sup>1,2</sup> remains the most powerful synthetic method for constructing important heterocyclic pharmacophores.<sup>3</sup> Our interest in the chemistry of ynamides<sup>4,6</sup> has led us to

develop [3 + 2] cycloadditions employing ynamides for the synthesis of *de novo* amide-substituted *N*-heterocycles. Particularly, we investigated Huisgen's organic azide-[3 + 2] cycloadditions<sup>7</sup> of ynamides given the emerging interest in this classic transformation as being a "click" reaction with industrial relevance.<sup>8,9</sup> We were able to develop CuSO<sub>4</sub>·5H<sub>2</sub>O-catalyzed tandem azidation of aryl [or vinyl] halides-azide [3 + 2] cycloaddition,<sup>10</sup> an *in situ* generation of organic azides from NaN<sub>3</sub> and alkyl halides to broaden the synthetic scope of the cycloaddition,<sup>11</sup> and a triazole templated ring-closing metathesis by trapping the triazolyl copper intermediate with allyl halides<sup>12</sup> leading to the synthesis of a diverse array of highly substituted, fused, or bridged triazoles (**Scheme 1**). With these initial successes, we continued to explore [3 + 2] cycloadditions of nitrile oxides<sup>14-16</sup> and  $\alpha$ -diazooacetates<sup>17,18</sup> with ynamides<sup>19-21</sup> for syntheses of amide-substituted isoxazoles<sup>22</sup> and pyrazoles (**Scheme 2**). We report here details of these findings.

**Scheme 1.** Huisgen's Azide-[3 + 2] Cycloaddition of Ynamides



**Scheme 2.** Cycloadditions with Nitrile Oxide and Ethyl  $\alpha$ -Diazooacetate




## RESULTS AND DISCUSSION


### 1. Ynamide-[3 + 2] Cycloaddition with Nitrile Oxides

The feasibility of a [3 + 2] cycloaddition of an ynamide with a nitrile oxide was readily established. As shown in **Scheme 3**, by employing Cu(I)-catalyzed conditions specifically featuring  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$  and Na-ascorbate as the reductant,<sup>15</sup> chiral ynamide **7**, substituted with Close' auxiliary,<sup>23</sup> reacted effectively with nitrile oxide **8**, which was generated *in situ* from  $\alpha$ -chloro oxime **6**, to provide 3,5-disubstituted isoxazole **11** in 85% yield as a single regioisomer. The 3,5-regioselectivity found in **11** was unambiguously assigned via its X-ray structure (**Figure 1**). The regiochemical outcome observed here is related to Fokin-Sharpless' work.<sup>15</sup> It is likely a result of copper-acetylide formation (see **9**) en route to a copper-directed or templated cycloaddition via intermediate **A** (see the bracket), leading to the vinyl copper intermediate **10** prior to the protonation from the solvent.

**Scheme 3.** Cu(I)-Catalyzed [3 + 2] Cycloaddition with Nitrile Oxide




**Figure 1.** Single Crystal X-Ray Structure of Isoxazole **11**



The generality of Cu(I)-catalyzed [3 + 2] cycloadditions of ynamides with nitrile oxides is summarized in **Figure 2**. All these cycloadditions were highly regioselective, leading to 5-amide-substituted isoxazoles exclusively without any 4-amide-substituted isoxazoles. There are two major features showcased here. Firstly, a range of different ynamides can be utilized in this cycloaddition and they are: An Evans' auxiliary-substituted<sup>24</sup> ynamide (see **12** - the red portion of isoxazoles originates from the respective ynamide), *N*-Bn, *N*-allyl, and *N*-indolyl ethyl sulfonyl-substituted ynamides (see **13**, **14**, and **16**), an electron-deficient indolyl ynamine (see **15**), and a vinylogous ynamide (see **17**).

**Figure 2.** Syntheses of 5-Amide-Substituted Isoxazoles




Secondly, the scope for the nitrile oxide (see the blue portion of isoxazoles) is very broad, ranging from electron-rich (see **17** and **18**) to electron-poor (see **19**) aryl-substituted nitrile oxides, a styryl-substituted nitrile oxide (see **20**), simple alkyl-substituted nitrile oxides (see **21-23**), and to electron-deficient nitrile oxide (see **24** and **25**). The yields of these cycloaddition reactions in general are very good with the exception of **24** and **25**. In addition to the medicinal significance of amide-substituted isoxazoles, The chiral amide-substituted isoxazoles prepared here should find applications as useful synthetic building blocks.<sup>14,25</sup>

## 2. Ynamide-[3 + 2] Cycloadditions with Ethyl $\alpha$ -Diazoacetate


With the success in achieving [3 + 2] cycloadditions with nitrile oxides, we investigated the synthesis of amide-substituted pyrazoles via [3 + 2] cycloadditions of ethyl  $\alpha$ -diazoacetate. With Ready's beautiful work<sup>17a</sup> appearing recently using copper(I) iodide as the catalyst, we elected to pursue thermal version of

this cycloaddition. As shown in **Scheme 4**, by heating chiral ynamide **26** with ethyl  $\alpha$ -diazooacetate at 110 °C for 18 h, pyrazole **28** was isolated in 43% yield as a single regioisomer. The generality of this cycloaddition should not be an issue as evident in the preparation of pyrazoles **29** in 52% yield from ynamide **27** under the same reaction conditions. However, instead of pursuing more examples, we became more interested in these new pyrazoles structurally.

**Scheme 4.** Cycloadditions of Ynamides with an  $\alpha$ -Diazoacetate




**Figure 3.** Single Crystal X-Ray Structure of Pyrazole **28**



As shown in **Figure 3**, the structural assignment for pyrazole **28**, based on its single crystal X-ray structure, clearly implies that there was an unusual tautomerization. Specifically, to arrive at pyrazole **28**, the initial cycloaddition intermediate **30** had to undergo a 1,5-hydrogen shift instead of 1,3-shift or tautomerization, leading to pyrazole **30** (**Scheme 5**). From the onset, there are no obvious structural elements that would bias one or the other, and both are capable of internal hydrogen bonding (see the dotted lines). Such a shift was also observed in Ready's work<sup>17a</sup> in their Cu(I)-catalyzed cycloadditions. The initial copper bond cycloaddition intermediate **B** also underwent the related shift en route to the same tautomer in which the NH group is adjacent to the ethoxycarbonyl group from the original  $\alpha$ -diazoacetate.


Li's elegant work<sup>17b</sup> in [3 + 2] cycloadditions of  $\alpha$ -diazoacetates with alkynes using  $\text{InCl}_3$  as the catalyst also revealed a similar shift of aryl and acyl groups.


**Scheme 5.** A Comparison of Regioselectivity



In addition to this tautomerization issue, while our regioselectivity is the same as Ready's Cu(I)-catalyzed cycloadditions, it is different from Huisgen's original work<sup>20</sup> using ynamines that provided pyrazole **33**. In our case, we do not see the related regioisomeric pyrazoles such as **32a/b** (the two possible tautomers). We attributed this difference to the fact that we used terminally unsubstituted ynamides, whereas Huisgen used a terminally substituted ynamine. Unfortunately, when we evaluated terminally substituted ynamides such as **34** (Scheme 6), we could not succeed in any of the cycloadditions using a range of conditions including Lewis and Brønsted acidic conditions.<sup>26</sup> This is in direct contrast to the Huisgen azide-[3 + 2] cycloaddition of ynamides in which we were able to effect the transformation for both terminally unsubstituted and substituted ynamides.<sup>10</sup>

**Scheme 6.** Cycloadditions of Terminally Substituted Ynamides



**Scheme 7.** [3 + 2] Cycloadditions of Push-Pull-Ynamides

Intriguingly, when we investigated cycloadditions of push-pull ynamides **36** and **37** with ethyl  $\alpha$ -diazoacetate, we were able to isolate the respective trisubstituted pyrazoles in high yields (**Scheme 7**). In addition, we were able to use Lewis acids such as  $\text{Zn}(\text{OTf})_2$  (10 mol%) to promote the cycloaddition,<sup>27</sup> although the yield was lower. These cycloadditions did provide both possible regioisomers, thereby in part suggesting that terminally substituted ynamides can alter the regioselectivity, although these push-pull ynamides likely carry a different electronic profile. Like those amide-substituted isoxazoles shown in the previous section, the chiral amide-substituted pyrazoles prepared here should also find applications as useful synthetic building blocks.<sup>14,28</sup>

## CONCLUSION

We have described here highly regioselective [3 + 2] cycloadditions of terminally unsubstituted ynamides with nitrile oxides and ethyl  $\alpha$ -diazoacetate to synthesize 5-amide-substituted isoxazoles and 3-amide-substituted pyrazoles, respectively through Cu(I)-catalyzed and thermal conditions.

## EXPERIMENTAL

All reactions were performed in flame-dried glassware under a nitrogen atmosphere. Solvents were distilled prior to use. Reagents were used as purchased (Aldrich, Acros), except where noted. Chromatographic separations were performed using Bodman 60 Å  $\text{SiO}_2$ .  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were obtained on Varian VI-300, VI-400, and VI-500 spectrometers using  $\text{CDCl}_3$  (except where noted) with TMS or residual  $\text{CHCl}_3$  in the solvent as standard. Melting points were determined using a Laboratory Devices MEL-TEMP and are uncorrected/calibrated. Infrared spectra were obtained using NaCl plates on a Bruker Equinox 55/S FT-IR Spectrophotometer, and relative intensities are expressed qualitatively as s (strong), m (medium), and w (weak). TLC analysis was performed using Aldrich 254 nm

polyester-backed plates (60 Å, 250 µm) and visualized using UV and a suitable chemical stain. Low-resolution mass spectra were obtained using an Agilent-1100-HPLC/MSD and can be either APCI or ESI, or an IonSpec HiRes-MALDI FT-Mass Spectrometer. High-resolution mass spectral analyses were performed at University of Wisconsin Mass Spectrometry Laboratories. All spectral data obtained for new compounds are reported. X-Ray analyses were performed at the X-Ray facility in University of Minnesota.

### General Procedure for [3 + 2] Cycloadditions of Ynamides with Nitrile Oxides.

To a vial equipped with 1.0 equiv of terminal ynamide, 0.1 equiv of CuSO<sub>4</sub>·5H<sub>2</sub>O, 0.2 equiv of Na-ascorbate and 2.0 equiv of K<sub>2</sub>CO<sub>3</sub> in *t*-BuOH/H<sub>2</sub>O (1:1) solution was added 1.30 equiv of the respective α-chloro oxime. After the mixture was stirred for 12 h, and TLC showed that the starting ynamide was all consumed, the reaction mixture was poured into dilute aq NH<sub>4</sub>Cl, and then extracted by EtOAc (3 x equal volume). The combined organic layers were washed with sat aq NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of solvent under reduced pressure gave crude isoxazole, which was purified via silica gel column flash chromatography with EtOAc/hexane as gradient eluent.

### Characterizations of New Isoxazoles.

**Isoxazole 11 [Yield: 85%].** *R<sub>f</sub>* = 0.53 [50% EtOAc in hexanes]; mp 196-198 °C; [α]<sub>D</sub><sup>20</sup> -31.3 (*c* 4.25, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.89 (d, 3 H, *J* = 6.5 Hz), 2.90 (s, 3 H), 4.08 (qd, 1 H, *J* = 6.5, 8.5 Hz), 5.41 (d, 1 H, *J* = 8.5 Hz), 6.68 (s, 1 H), 7.24 (d, 2 H, *J* = 6.5 Hz), 7.31-7.38 (m, 3 H), 7.42-7.46 (m, 3 H), 7.78-7.82 (m, 2 H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 15.1, 28.8, 55.9, 61.1, 84.6, 126.9, 127.5, 128.9, 129.0, 129.1, 129.6, 130.2, 135.8, 155.7, 162.4, 163.6; IR (film) cm<sup>-1</sup> 2975w, 1717s, 1601s, 1581m, 1481w, 1446s, 1421s, 1303m, 1263s, 1120m, 1078m, 1010m; mass spectrum (MALDI): *m/e* (% relative intensity) 334.2 (100) (M + H)<sup>+</sup>; HRMS (MALDI) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> 334.1550, found 334.1540.

**Isoxazole 12 [Yield: 80%].** *R<sub>f</sub>* = 0.52 [33% EtOAc in hexanes]; mp 169-171 °C; [α]<sub>D</sub><sup>20</sup> -63.3 (*c* 1.84, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.39 (dd, 1 H, *J* = 4.4, 8.8 Hz), 4.84 (dd, 1 H, *J* = 8.8, 8.8 Hz), 5.53 (dd, 1 H, *J* = 4.4, 8.8 Hz), 6.65 (s, 1 H), 7.34-7.42 (m, 8 H), 7.72-7.75 (m, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 59.3, 71.3, 86.9, 126.4, 126.9, 129.0, 129.1, 129.6, 129.7, 130.5, 138.0, 153.2, 160.4, 163.8; IR (film) cm<sup>-1</sup> 2852w, 1684s, 1542s, 1514m, 1415m, 1358m, 1229s, 1137s, 1101m, 1063m, 1041m; mass spectrum (MALDI): *m/e* (% relative intensity) 307.1 (100) (M + H)<sup>+</sup>; HRMS (MALDI) calcd for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> 307.1077, found 307.1070.

**Isoxazole 13 [Yield: 85%].** *R<sub>f</sub>* = 0.67 [33% EtOAc in hexanes]; mp 157-159 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.47 (s, 3 H), 5.00 (s, 2 H), 6.51 (s, 1 H), 7.30-7.38 (m, 5 H), 7.44-7.50 (m, 5 H), 7.73 (d, 2 H, *J*

= 8.0 Hz), 7.77-7.81 (m, 2 H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  21.9, 52.6, 93.3, 126.9, 127.6, 128.5, 128.8, 129.0, 129.1, 129.2, 130.3, 130.6, 135.2, 135.5, 145.2, 162.6, 163.9; IR (film)  $\text{cm}^{-1}$  2924w, 1701m, 1596s, 1575s, 1495w, 1470m, 1456w, 1412m, 1360s, 1341m, 1291m, 1167s, 1085m, 1044m; mass spectrum (MALDI):  $m/e$  (% relative intensity) 405.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_3\text{SNa}$  427.1087, found 427.1093.

**Isoxazole 14 [Yield: 82%].**  $R_f$  = 0.36 [20% EtOAc in hexanes];  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  2.41 (s, 3 H), 4.38 (d, 2 H,  $J$  = 6.0 Hz), 5.21 (dd, 1 H,  $J$  = 1.0, 10.0 Hz), 5.32 (dd, 1 H,  $J$  = 1.0, 18.0 Hz), 5.81-5.90 (m, 1 H), 6.50 (s, 1 H), 7.29 (d, 2 H,  $J$  = 8.0 Hz), 7.43-7.46 (m, 3 H), 7.71 (d, 2 H,  $J$  = 8.0 Hz), 7.76-7.78 (m, 2 H);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  21.9, 51.6, 92.7, 120.1, 126.9, 127.7, 129.1, 129.2, 130.3, 130.6, 131.8, 135.5, 145.2, 162.8, 164.0; IR (film)  $\text{cm}^{-1}$  2361(m), 1597(s), 1576(s), 1475(w), 1445(w), 1408(m), 1362(s), 1166(s), 1089(m), 1049(m); mass spectrum (APCI):  $m/e$  (% relative intensity) 355.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_3\text{SNa}$  377.0930, found 377.0942.

**Isoxazole 15 [Yield: 22%].**  $R_f$  = 0.38 [15% EtOAc in hexanes]; mp 87-89  $^{\circ}\text{C}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.31 (t, 3 H,  $J$  = 7.2 Hz), 4.32 (q, 2 H,  $J$  = 7.2 Hz), 6.70 (s, 1 H), 7.26-7.31 (m, 1 H), 7.35-7.43 (m, 2 H), 7.48-7.54 (m, 4 H), 7.74 (d, 1 H,  $J$  = 7.2 Hz), 7.88-7.90 (m, 2 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  14.4, 61.5, 97.2, 111.6, 114.6, 123.0, 123.1, 127.0, 127.1, 127.2, 129.2, 129.3, 129.6, 130.6, 139.8, 160.6, 161.2, 163.9; IR (film)  $\text{cm}^{-1}$  2361m, 1711s, 1632s, 1611w, 1582m, 1470m, 1264m, 1212m, 1180m, 1147m, 1032m; mass spectrum (APCI):  $m/e$  (% relative intensity) 333.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_3$  333.1239, found 333.1238.

**Isoxazole 16 [Yield: 24%].**  $R_f$  = 0.53 [50% EtOAc in hexanes];  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.45 (s, 3H), 3.14-3.18 (m, 2H), 4.00-4.04 (m, 2H), 6.11 (s, 1H), 7.01 (d, 1H,  $J$  = 2.4 Hz), 7.13 (td, 1H,  $J$  = 7.2, 1.2 Hz), 7.17 (td, 1H,  $J$  = 7.8, 1.6 Hz), 7.22 (d, 2H,  $J$  = 8.0 Hz), 7.31 (d, 1H,  $J$  = 8.0 Hz), 7.43-7.46 (m, 3H), 7.67 (d, 3H,  $J$  = 8.4Hz), 7.76-7.78 (m, 2H), 8.16 (s, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  21.9, 25.8, 49.9, 92.5, 111.5, 111.8, 119.0, 19.9, 122.4, 122.8, 126.9, 127.5, 129.1, 129.2, 130.3, 130.6, 135.5, 136.5, 145.1, 163.0, 164.1 [missing 1 carbon due to overlap]; IR (film)  $\text{cm}^{-1}$  3411w, 3057w, 2923w, 2854w, 2361w, 1774w, 1597m, 1567m, 1406m, 1165s; mass spectrum (APCI):  $m/e$  (% relative intensity) 458.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{26}\text{H}_{23}\text{N}_3\text{O}_3\text{SNa}$  480.1352, found 480.1373.

**Isoxazole 17 [Yield: 68%].**  $R_f$  = 0.19 [50% EtOAc in hexanes]; mp 150-156  $^{\circ}\text{C}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  2.24 (quintet, 2H,  $J$  = 6.3 Hz), 2.56 (dd, 2H,  $J$  = 7.4, 5.7 Hz), 3.08 (t, 2H,  $J$  = 6.2 Hz), 3.88 (s, 3H), 6.31 (s, 1H), 6.75 (d, 1H,  $J$  = 3.4 Hz), 7.01 (dd, 2H,  $J$  = 8.9, 2.1 Hz), 7.07 (d, 1H,  $J$  = 3.4 Hz), 7.76 (d, 2H,  $J$  = 8.9, 2.1 Hz);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  23.5, 23.7, 37.8, 55.7, 89.1, 108.9, 114.8, 121.0,

121.5, 123.9, 128.5, 143.1, 161.4, 161.8, 163.7, 194.5; IR (film)  $\text{cm}^{-1}$  2925m, 1738w, 1663s, 1615s, 1554m, 1531m, 1505w, 1478w, 1448m, 1434s, 1408m, 1351w, 1279s, 1256s, 1173m, 1151w, 1116w, 1101m, 1023m; mass spectrum (APCI):  $m/e$  (% relative intensity) 309.2 (100) ( $M + H$ )<sup>+</sup>, 150.2 (10), 136.2 (30); HRMS (MALDI) calcd for  $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_3$  309.1239, found 309.1247.

**Isoxazole 18 [Yield: 86%].**  $R_f = 0.23$  [25% EtOAc in hexanes]; mp 148–153 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.41 (s, 3H), 3.83 (s, 3H), 4.91 (s, 2H), 6.38 (s, 1H), 6.93 (ddd, 2H,  $J = 9.6, 2.8, 2.8\text{Hz}$ ), 7.26–7.32 (m, 5H), 7.39 (dd, 2H,  $J = 8.4, 2.0\text{Hz}$ ), 7.64–7.67 (m, 4H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  21.9, 52.5, 55.6, 93.1, 114.5, 121.5, 127.6, 128.3, 128.4, 128.7, 128.9, 130.2, 135.2, 135.5, 145.1, 161.4, 162.3, 163.5; IR (film)  $\text{cm}^{-1}$  3670w, 3055w, 2981m, 2887w, 2361w, 2341w, 1701w, 1597m, 1168s; mass spectrum (APCI):  $m/e$  (% relative intensity) 435.1 (100) ( $M + H$ )<sup>+</sup>; HRMS (MALDI) calcd for  $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$  435.1373, found 435.1391.

**Isoxazole 19 [Yield: 83%].**  $R_f = 0.65$  [50% EtOAc in hexanes]; mp 153–155 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.43 (s, 3H), 4.95 (s, 2H), 6.50 (s, 1H), 7.25 – 7.33 (m, 5H), 7.39 (ddd, 2H,  $J = 8.4, 2.0, 2.0\text{Hz}$ ), 7.67 (ddd, 2H,  $J = 8.4, 2.0, 2.0\text{Hz}$ ), 7.91 (ddd, 2H,  $J = 8.8, 2.0, 2.0\text{Hz}$ ) 8.29 (ddd, 2H,  $J = 8.8, 2.0, 2.0\text{Hz}$ );  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  21.9, 52.5, 92.8, 124.4, 127.5, 127.7, 128.5, 128.6, 129.0, 130.3, 134.9, 135.0, 135.3, 145.4, 149.0, 162.1, 163.6; IR (film)  $\text{cm}^{-1}$  3652w, 3063w, 2981w, 2360w, 2341w, 1585m, 1496m, 1342s, 1168s; mass spectrum (APCI):  $m/e$  (% relative intensity) 450.1 (100) ( $M + H$ )<sup>+</sup>; HRMS (MALDI) calcd for  $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}_5\text{SNa}$  472.0938, found 472.0950.

**Isoxazole 20 [Yield: 52%].**  $R_f = 0.08$  [25% EtOAc in hexanes]; mp 100–104 °C;  $[\alpha]_{\text{D}}^{20} -19.2$  ( $c$  1.00,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.39 (dd, 1H,  $J = 8.8, 4.4\text{Hz}$ ), 4.87 (t, 1H,  $J = 8.8\text{Hz}$ ), 5.52 (dd, 1H,  $J = 8.8, 4.8\text{Hz}$ ), 6.57 (s, 1H), 6.94 (d, 1H,  $J = 16.8\text{Hz}$ ), 7.15 (d, 1H,  $J = 20.4\text{Hz}$ ), 7.26–7.49 (m, 5H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  59.3, 71.3, 85.9, 115.9, 126.4, 127.1, 127.3, 129.1, 129.3, 129.6, 135.9, 137.0, 138.0, 153.2, 159.8, 163.3; IR (film)  $\text{cm}^{-1}$  3035w, 2251w, 2155w, 1774s, 1604m, 1472m, 1453s, 1397m, 1205m; mass spectrum (APCI):  $m/e$  (% relative intensity) 333.1 (100) ( $M + H$ )<sup>+</sup>; HRMS (MALDI) calcd for  $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_3$  332.1161, found 332.1150.

**Isoxazole 21 [Yield: 61%].**  $R_f = 0.38$  [50% EtOAc in hexanes]; mp 127–130 °C;  $[\alpha]_{\text{D}}^{20} -74.5$  ( $c$  1.82,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.20 (s, 3H), 4.37 (dd, 1H,  $J = 4.4, 8.8\text{Hz}$ ), 4.84 (t, 1H,  $J = 8.8\text{Hz}$ ), 5.48 (dd, 1H,  $J = 4.4, 8.8\text{Hz}$ ), 6.14 (s, 1H), 7.31–7.40 (m, 5H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  12.0, 59.2, 71.2, 89.6, 126.4, 129.5, 129.6, 138.1, 153.2, 159.7, 161.7; IR (film)  $\text{cm}^{-1}$  3529w, 3162w, 2362w, 1768s, 1607m, 1482m, 1504m, 1378s, 1207s; mass spectrum (APCI):  $m/e$  (% relative intensity) 245.1 (100) ( $M + H$ )<sup>+</sup>; HRMS (MALDI) calcd for  $\text{C}_{13}\text{H}_{12}\text{N}_2\text{O}_3\text{Na}$  267.0740, found 267.0742.

**Isoxazole 22 [Yield: 34%].**  $R_f = 0.31$  [25% EtOAc in hexanes]; mp 149-151 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  2.18 (s, 3H), 2.42 (s, 3H), 4.86 (s, 2H), 5.92 (s, 1H) 7.25 – 7.30 (m, 5H), 7.34 (dd, 2H,  $J = 8.0$ , 2.0Hz), 7.62 (ddd, 2H,  $J = 8.4$ , 2.0, 2.0Hz);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  12.2, 21.9, 52.4, 96.0, 127.6, 128.3, 128.6, 128.8, 130.2, 135.3, 135.5, 145.0, 161.8, 161.9; IR (film)  $\text{cm}^{-1}$  3666w, 3132w, 3053w, 2361w, 1598m, 1373s, 1263m, 1164s; mass spectrum (APCI):  $m/e$  (% relative intensity) 343.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_3\text{SNa}$  365.0930, found 365.0933.

**Isoxazole 23 [Yield: 55%].**  $R_f = 0.30$  [25% EtOAc in hexanes];  $[\alpha]_D^{20} -58.1$  ( $c$  2.81,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.85-0.90 (m, 3H), 1.25-1.32 (m, 4H), 1.59-1.63 (m, 2H), 2.54 (t, 2H,  $J = 7.2$  Hz), 4.36 (dd, 1H,  $J = 8.8$ , 4.4Hz), 4.86 (t, 1H,  $J = 8.8$ Hz), 5.48 (dd, 1H,  $J = 8.8$ , 4.4Hz), 6.16 (s, 1H), 7.32-7.40 (m, 5H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  14.1, 22.5, 26.6, 27.8, 31.5, 59.2, 71.2, 88.4, 126.4, 129.5, 129.6, 138.2, 153.2, 159.6, 166.0; IR (neat)  $\text{cm}^{-1}$  3159w, 2957w, 2930w, 2860w, 2360w, 2341w, 1774s, 1606s, 1497m, 1364s; mass spectrum (APCI):  $m/e$  (% relative intensity) 301.2 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{17}\text{H}_{20}\text{N}_2\text{O}_3\text{Na}$  323.1366, found 323.1372.

**Isoxazole 24 [Yield: 31%].**  $R_f = 0.59$  [50% EtOAc in hexanes]; mp 71-74 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.38 (t, 3H,  $J = 7.2$  Hz), 2.43 (s, 3H), 4.39 (q, 2H,  $J = 7.2$  Hz), 4.91 (s, 2H), 6.48 (s, 1H), 7.27-7.34 (m, 7H) 7.63 (ddd, 2H,  $J = 8.4$ , 2.0, 2.0Hz);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  14.3, 21.9, 52.6, 62.5, 95.4, 127.6, 128.6, 128.7, 129.0, 130.3, 134.7, 135.1, 145.5, 157.8, 159.7, 163.8; IR (film)  $\text{cm}^{-1}$  3657w, 3157w, 2980m, 2886w, 2361w, 1733m, 1585m, 1496m, 1253m, 1187s; mass spectrum (APCI):  $m/e$  (% relative intensity) 401.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_5\text{SNa}$  423.0985, found 423.1000.

**Isoxazole 25 [Yield: 34%].**  $R_f = 0.12$  [25% EtOAc in hexanes]; mp 69-78 °C;  $[\alpha]_D^{20} -70.2$  ( $c$  2.25,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.37 (t, 3H,  $J = 6.0$ Hz), 4.38 (dq, 2H,  $J = 6.0$ , 1.6Hz), 4.43 (dd, 1H,  $J = 7.2$ , 3.6Hz), 4.90 (t, 1H,  $J = 7.2$ Hz), 5.54 (dd, 1H,  $J = 6.8$ , 3.6Hz), 6.68 (s, 1H), 7.33-7.41 (m, 5H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  14.3, 57.7, 63.1, 70.7, 89.5, 126.3, 129.2, 129.5, 137.4, 152.8, 157.7, 159.7, 161.5; IR (film)  $\text{cm}^{-1}$  2985w, 2360w, 2340w, 1782s, 1737m, 1604m, 1480m, 1397m, 1366w; mass spectrum (APCI):  $m/e$  (% relative intensity) 303.1 (100) ( $\text{M} + \text{H}$ ) $^+$ ; HRMS (MALDI) calcd for  $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_5\text{Na}$  325.0795, found 325.0798.

#### General Procedure for [3 + 2] Cycloadditions of Ynamides with $\alpha$ -Diazo-Acetate.

To a solution of ynamide **26** (50.0 mg, 0.27 mmol) in toluene (2.0 mL) was added ethyl  $\alpha$ -diazoacetate (0.037 mL, 0.32 mmol). The reaction was heated to 110 °C in a sealed vial and stirred for 18 h. The solvent was then removed under reduced pressure and the resulting oil was purified via silica gel column

flash chromatography (gradient eluent: 30-50% EtOAc in hexanes) to afford the pyrazole **28** (35.0 mg, 43%) as a white solid.

### Characterizations of New Pyrazoles.

**Pyrazole 28 [Yield: 43%].**  $R_f = 0.29$  [40% EtOAc in hexanes]; mp 147-149 °C;  $[\alpha]_D^{20} -89.0$  (*c* 6.80, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.32 (t, 3 H, *J* = 7.2 Hz), 4.25 (dd, 1 H, *J* = 4.8, 8.8 Hz), 4.31 (q, 2 H, *J* = 7.2 Hz), 4.76 (dd, 1 H, *J* = 8.8, 8.8 Hz), 5.53 (dd, 1 H, *J* = 4.8, 8.8 Hz), 7.10 (brs, 1 H), 7.24-7.33 (m, 5 H), 11.57 (brs, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 14.0, 59.1, 61.5, 70.7, 99.0, 125.9, 128.5, 129.0, 135.3, 138.7, 146.5, 155.1, 159.5; IR (film) cm<sup>-1</sup> 1764s, 1725s, 1511m, 1120w, 1156w; mass spectrum (APCI): *m/e* (% relative intensity) 302.1 (100) (M + H)<sup>+</sup>; HRMS (MALDI) calcd for C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>Na 324.0955, found 324.0959.

**Pyrazole 29 [Yield: 52%].**  $R_f = 0.49$  [40% EtOAc in hexanes]; mp 165-167 °C;  $[\alpha]_D^{20} 283$  (*c* 2.50, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.38 (t, 3 H, *J* = 7.2 Hz), 3.40 (d, 2 H, *J* = 3.6 Hz), 4.39 (q, 2 H, *J* = 7.2 Hz), 5.39-5.44 (m, 1 H), 5.99 (d, 1 H, *J* = 7.6 Hz), 7.15 (dd, 1 H, *J* = 7.6, 7.6 Hz), 7.22 (s, 1 H), 7.25-7.33 (m, 2 H), 7.63 (d, 1 H, *J* = 7.6 Hz), 10.26 (bs, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 14.4, 38.5, 62.0, 64.4, 78.9, 99.2, 125.6, 126.9, 127.9, 129.9, 135.4, 139.0, 140.3, 147.6, 154.5, 159.9; IR (film) cm<sup>-1</sup> 1721s, 1509m, 1420w, 1173m, 1152m; mass spectrum (APCI): *m/e* (% relative intensity) 314.1 (100) (M + H)<sup>+</sup>; HRMS (MALDI) calcd for C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>Na 336.0955, found 336.0961.

**Pyrazole 38a/b [Yield: 79%].**  $R_f = 0.18$  [40% EtOAc in hexanes]; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) **38a**: δ 1.43 (t, 3 H, *J* = 7.5 Hz), 2.53 (s, 3 H), 4.34-4.46 (m, 3 H), 4.88 (dd, 1 H, *J* = 8.5, 9.0 Hz), 5.81 (dd, 1 H, *J* = 8.5, 9.0 Hz), 7.24-7.40 (m, 5 H), 11.40 (brs, 1 H); **38b**: δ 1.36 (t, 3 H, *J* = 7.5 Hz), 2.55 (brs, 3 H), 4.26 (dd, 1 H, *J* = 7.5, 8.5 Hz), 4.34-4.46 (m, 2 H), 4.83 (dd, 1 H, *J* = 8.5, 9.0 Hz), 5.59 (dd, 1 H, *J* = 7.5, 8.5 Hz), 7.24-7.40 (m, 5 H), 11.40 (brs, 1 H); IR (film) cm<sup>-1</sup> 1723m, 1687s, 1465m, 1395m; mass spectrum (APCI): *m/e* (% relative intensity) 344.1 (100) (M + H)<sup>+</sup>; HRMS (MALDI) calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>5</sub>Na 366.1060, found 366.1063.

**Pyrazole 39a/b [Yield: 85%].**  $R_f = 0.20$  [40% EtOAc in hexanes]; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) **39a**: δ 1.14 (t, 3 H, *J* = 7.0 Hz), 1.41 (t, 3 H, *J* = 7.5 Hz), 2.95 (q, 2 H, *J* = 7.0 Hz), 4.30-4.44 (m, 3 H), 4.87 (dd, 1 H, *J* = 8.5, 9.0 Hz), 5.81 (dd, 1 H, *J* = 8.5, 8.5 Hz), 7.22-7.42 (m, 5 H), 11.50 (brs, 1 H); **39b**: δ 1.14 (t, 3 H, *J* = 7.0 Hz), 1.33 (t, 3 H, *J* = 7.0 Hz), 3.01 (q, 1 H, *J* = 7.0 Hz), 3.05 (q, 1 H, *J* = 7.0 Hz), 4.23 (dd, 1 H, *J* = 8.0, 8.5 Hz), 4.30-4.44 (m, 2 H), 4.81 (dd, 1 H, *J* = 8.5, 9.0 Hz), 5.59 (dd, 1 H, *J* = 8.0, 9.0 Hz), 7.22-7.42 (m, 5 H), 11.50 (brs, 1 H); IR (film) cm<sup>-1</sup> 1725m, 1688s, 1459m, 1399m; mass spectrum (APCI): *m/e* (% relative intensity) 358.1 (100) (M + H)<sup>+</sup>; HRMS (MALDI) calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>5</sub>Na

380.1217, found 380.1217.

## ACKNOWLEDGEMENTS

Authors thank NIH [GM066055] and UW-Madison for funding, and Mr. Benjiman E. Kucera and Dr. Vic Young at University of Minnesota for providing X-ray structural analyses.

## REFERENCE

1. For reviews, see: (a) I. Coldham, and R. Hufton, *Chem. Rev.*, 2005, **105**, 2765. (b) K. Ruch-Braun, T. H. E. Freysoldt, and F. Wierschem, *Chem. Soc. Rev.*, 2005, **34**, 507. (c) A. I. Kotyatkina, V. N. Zhabinsky, and V. A. Khripach, *Russ. Chem. Rev.*, 2005, **34**, 507. (d) M. Harmata and Rashatasakhon, *P. Tetrahedron*, 2003, **59**, 2371. (e) H. M. L. Davies, 'Advances in Cycloaddition,' Vol. 5 ed. by M. Harmata, JAI Press: 1998, pp. 119-164. (f) K. V. Gothelf and K. A. Jørgensen, *Chem. Rev.*, 1998, **98**, 863. (g) F. G. West, 'Advances in Cycloaddition,' Vol. 4, ed. by M. Lautens, JAI: Greenwich, 1997, 1. (h) J. H. Rigby and F. C. Pigge, *Organic React.*, 1997, **51**, 351. (i) A. Padwa, 'Comprehensive Organic Synthesis,' Vol. 4 ed. by B. M. Trost, Pergamon Press, Oxford, 1991, pp. 1069-1109. (k) W. Carruthers, 'Cycloaddition Reactions in Organic Synthesis,' Pergamon Press: New York, 1990, pp. 270-331. (j) A. Padwa, '1,3-Dipolar Cycloaddition Chemistry,' Vol 1, John Wiley and Sons; New York, 1984.
2. For related reviews on cycloadditions: (a) J. A. Varela and C. Saá, *Chem. Rev.*, 2003, **103**, 3787. (b) M. Rubin, A. W. Sromek, and V. Gervorgyan, *Synlett*, 2003, 2265. (c) C. Aubert, O. Buisine, and M. Malacria, *Chem. Rev.*, 2002, **102**, 813. (d) S. Saito and Y. Yamamoto, *Chem. Rev.*, 2000, **100**, 2901.
3. (a) For a review, see: W.-Q. Fan and A. R. Katritzky, 'Comprehensive Heterocyclic Chemistry,' Vol. 4, ed. by A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, Pergamon Press, Oxford, 1996, pp. 101-126. For some examples, see: (b) J. H. Cho, D. L. Bernard, R. W. Sidwell, E. R. Kern, and C. K. Chu, *J. Med. Chem.*, 2006, **49**, 1140. (c) F. Pagliai, T. Pirali, E. Del Grosso, R. Di Brisco, G. C. Tron, G. Sorba, and A. A. Genazzani, *J. Med. Chem.*, 2006, **49**, 467. (d) A. Brik, J. Muldoon, Y.-C. Lin, J. H. Elder, D. S. Goodsell, A. J. Olson, V. V. Fokin, K. B. Sharpless, and C.-H. Wong, *ChemBioChem.*, 2003, **4**, 1246. (e) T. Takahashi, H. Fujimura, and A. Asai, *Yakugaku Zasshi*, 1962, **82**, 474. (f) S. Pinzauti, V. Dal Piaz, I. Berdondini, and L. Leni, *Bull. Chim. Farm.*, 1974, **113**, 26. (g) G. Daidone, B. Maggio, S. Plescia, D. Raffa, C. Musiu, C. Milia, G. Perra, and M. E. Marongiu, *Eur. J. Med. Chem.*, 1998, **33**, 375. (h) J. J. Parlow, *J. Heterocycl. Chem.*, 1998, **35**, 1493.
4. For reviews on ynamides, see: (a) C. A. Zifcick, J. A. Mulder, R. P. Hsung, C. Rameshkumar, and L.-L. Wei, *Tetrahedron*, 2001, **57**, 7575. (b) J. A. Mulder, K. C. M. Kurtz, and R. P. Hsung, *Synlett*, 2003, 1379. (c) A. R. Katritzky, R. Jiang, and S. K. Singh, *Heterocycles*, 2004, **63**, 1455. For a

- comprehensive review on the synthesis of ynamides, see: (d) M. R. Tracey, R. P. Hsung, J. Antoline, K. C. M. Kurtz, L. Shen, B. W. Slafer, and Y. Zhang, '*Science of Synthesis, Houben-Weyl Methods of Molecular Transformations*,' Chapter 21.4, ed. by S. M. Weinreb, Georg Thieme Verlag KG: Stuttgart, Germany, 2005.
5. For a special issue dedicated to the chemistry of ynamides, see: '*Tetrahedron-Symposium-In-Print: Chemistry of Electron-Deficient Ynamines and Ynamides*,' Issue No.16. *Tetrahedron*, 2006, **62**.
  6. For recent references on chemistry of ynamides, see: (a) D. Rodríguez, M. F. Martínez-Esperón, L. Castedo, and C. Saá, *Synlett*, 2007, 1963. (b) J. Oppenheimer, W. L. Johnson, M. R. Tracey, R. P. Hsung, P.-Y. Yao, R. Liu, and K. Zhao, *Org. Lett.*, 2007, **9**, 2361. (c) L. You, Z. F. Al-Rashid, R. Figueroa, S. K. Ghosh, G. Li, T. Lu, and R. P. Hsung, *Synlett*, 2007, 1656. (d) A. S. K. Hashimi, R. Salathe, and W. Frey, *Synlett*, 2007, 1763. (e) K. Tanaka, K. Takeishi, and K. Noguchi, *J. Am. Chem. Soc.*, 2006, **128**, 4586. (f) S. Couty, C. Meyer, and J. Cossy, *Angew. Chem. Int. Ed.*, 2006, **45**, 6726. (g) M. R. Tracey, J. Oppenheimer, and R. P. Hsung, *J. Org. Chem.*, 2006, **71**, 8629. (h) X. Zhang, Y. Zhang, J. Huang, R. P. Hsung, K. C. M. Kurtz, J. Oppenheimer, M. E. Petersen, I. K. Sagamanova, and M. R. Tracey, *J. Org. Chem.*, 2006, **71**, 4170. (i) K. C. M. Kurtz, R. P. Hsung, and Y. Zhang, *Org. Lett.*, 2006, **8**, 231. (j) J. R. Dunetz and R. L. Danheiser, *J. Am. Chem. Soc.*, 2005, **127**, 5776. (k) N. Riddell, K. Villeneuve, and W. Tam, *Org. Lett.*, 2005, **7**, 3681. (l) Y. Zhang, *Tetrahedron Lett.*, 2005, **46**, 6483. (m) H. Chechik-Lankin, S. Livshin, and I. Marek, *Synlett*, 2005, 2098. (n) Y. Zhang, R. P. Hsung, X. Zhang, J. Huang, B. W. Slafer, and A. Davis, *Org. Lett.*, 2005, **7**, 1047.
  7. (a) R. Huisgen, *Angew. Chem.*, 1963, **75**, 604. (b) R. Huisgen, '*1,3-Dipolar Cycloaddition Chemistry*,' ed. by A. Padwa, Pergamon Press, Oxford, 1984, pp .1-176.
  8. For recent reviews on azide-alkyne cycloadditions, see: (a) V. D. Bock, H. Hiemstra, and J. H. Van Maarseveen, *Eur. J. Org. Chem.*, 2006, 51. (b) A. R. Katritzky, Y. Zhang, and S. K. Singh, *Heterocycles*, 2003, **60**, 1225. (c) H. C. Kolb and K. B. Sharpless, *Drug Discovery Today*, 2003, **8**, 1128. (d) S. T. Abu-Orabi, *Molecule*, 2002, **7**, 302. (e) H. C. Kolb, M. G. Finn, and K. B. Sharpless, *Angew. Chem. Int. Ed.*, 2001, **40**, 2004. For a review on chemistry of organic azides, see: (f) S. Bräse, C. Gil, K. Knepper, and V. Zimmermann, *Angew. Chem. Int. Ed.*, 2005, **44**, 5188.
  9. For some recent examples, see: (a) V. D. Bock, R. Perciaccante, T. P. Jansen, H. Hiemstra, and J. H. Van Maarseveen, *Org. Lett.*, 2006, **8**, 919. (b) B. Gerard, J. Ryan, A. B. Beeler, and J. A. Jr. Porco, *Tetrahedron*, 2006, **62**, 6405. (c) M. P. Cassidy, J. Raushel, and V. V. Fokin, *Angew. Chem. Int. Ed.*, 2006, **45**, 3154. (d) E. J. Yoo, I. Bae, S. H. Cho, H. Han, and S. Chang, *Org. Lett.*, 2006, **8**, 1347. (e) I. Bae, H. Han, and S. Chang, *J. Am. Soc. Chem.*, 2005, **127**, 2038. (f) V. O. Rodionov, V. V. Fokin, and M. G. Finn, *Angew. Chem. Int. Ed.*, 2005, **44**, 2210. (g) L. Zhang, X. Chen, P. Xue, H. H. Y. Sun, I. D. Williams, K. B. Sharpless, V. V. Fokin, and G. Jia, *J. Am. Chem. Soc.*, 2005, **127**, 15998. (h) P. Wu,

- A. K. Feldman, A. K. Nugent, C. J. Hawker, A. Scheel, B. Voit, J. Pyun, J. M. J. Frechet, K. B. Sharpless, and V. V. Fokin, *Angew. Chem. Int. Ed.*, 2004, **43**, 3928. (i) A. K. Feldman, B. Colasson, and V. V. Fokin, *Org. Lett.*, 2004, **6**, 3897. (j) Q. Wang, T. R. Chan, R. Hilgraf, K. B. Sharpless, and V. V. Fokin, *J. Am. Chem. Soc.*, 2003, **125**, 3192. (k) V. Rostovtsev, L. G. Green, V. V. Fokin, and K. B. Sharpless, *Angew. Chem. Int. Ed.*, 2002, **41**, 2596.
10. X. Zhang, R. P. Hsung, and L. You, *Org. Biomol. Chem.*, 2006, **6**, 2679.
11. X. Zhang, H. Li, L. You, Y. Tang, and R. P. Hsung, *Adv. Syn. Cat.*, 2006, **348**, 2437.
12. X. Zhang, R. P. Hsung, and H. Li, *Chem. Commun.*, 2007, 2420.
13. For a beautiful earlier account of azide-[3 + 2] cycloadditions of ynamides, see: (a) M. IJsselstijn and J.-C. Cintrat, *Tetrahedron*, 2006, **62**, 3837. For some examples of ynamine-azide cycloadditions: (b) N. K. Markova, A. E. Tsil'ko, V. A. Galishev, I. A. Maretina, and A. A. Petrov, *Zh. Org. Khim.*, 1984, **20**, 404. (c) J. C. Chabala, B. G. Christensen, R. W. Ratcliffe, and M. F. Woods, *Tetrahedron Lett.*, 1985, **26**, 5407.
14. For reviews on nitrile oxides, see: (a) V. Jäger and P. A. Colinas, 'The Chemistry of Heterocyclic Compounds: Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products,' Vol 59, ed. by A. Padwa and W. H. Pearson, Wiley: New York, 2003, pp. 361-472. (b) P. G. Baradi, A. Barco, S. Benetti, G. P. Pollini, and D. Simoni, *Synthesis*, 1987, 857.
15. (a) F. Himo, T. Lovell, R. Hilgraf, V. O. Rodionov, L. Noodeman, K. B. Sharpless, and V. V. Fokin, *J. Am. Chem. Soc.*, 2005, **127**, 210. (b) T. V. Hansen, P. Wu, and V. V. Fokin, *J. Org. Chem.*, 2005, **70**, 7761.
16. D. Giguère, R. Patnam, M.-A. Bellefleur, C. St-Pierre, S. Sato, and R. Roy, *Chem. Commun.*, 2006, 2379.
17. For recent examples of [3 + 2] cycloadditions of diazo-compounds, see: (a) X. Qi and J. M. Ready, *Angew. Chem. Int. Ed.*, 2007, **46**, 3242. (b) N. Jiang and C.-J. Li, *Chem. Commun.*, 2004, 394. (c) V. K. Aggarwal, J. de Vicente, and R. V. Bonnert, *J. Org. Chem.*, 2003, **68**, 5381. (d) G. Maas and V. Gettwert, *Tetrahedron*, 2000, **56**, 4139. (e) A. S. Kende and M. Journet, *Tetrahedron Lett.*, 1995, **36**, 3087.
18. For a related work pyrazole synthesis using azomethine imine [3 + 2] cycloaddition., see: R. Shintani and G. C. Fu, *J. Am. Chem. Soc.*, 2003, **125**, 10778.
19. For earlier work on nitrile oxide [3 + 2] cycloadditions using ynamines, see: (a) L. N. Sukhova, I. G. Ostrumov, V. K. Bel'skii, and I. A. Maretina, *Russ. J. Org. Chem.*, 1994, **30**, 49. (b) L. N. Sukhova, I. G. Ostrumov, V. K. Bel'skii, I. A. Maretina, and V. A. Galishev, *Russ. J. Org. Chem.*, 1993, **29**, 1028. (c) G. Himbert, D. Faul, and M. Z. Barz, *Naturforsch.*, 1991, **46b**, 955. (d) G. Himbert, H. Kuhn, and M. Barz, *Liebigs Ann. Chem.*, 1990, 403.

20. For earlier work on pyrazole synthesis via [3 + 2] cycloadditions of diazo-compounds with using ynamines, see: (a) R. Huisgen, H.-U. Reissig, and H. Huber, *J. Am. Chem. Soc.*, 1979, **101**, 3647. (b) R. Huisgen, M. P. B. Verderol, A. Gieren, and V. Lamm, *Angew. Chem. Int. Ed.*, 1981, **20**, 694. (c) B. Tinant, J.-P. Declercq, M. Van Meerssche, A. Bouvy, Z. Janousek, and H. G. Viehe, *J. Chem. Soc., Perkin Trans. 2*, 1985, 1419.
21. For earlier work on pyrazole synthesis via hydrazine [3 + 2] cycloadditions using ynamines, see: E. N. Zakhartsova, A. N. Pankratov, I. G. Ostrumov, and I. A. Maretina, *Izv. Vyssh. Vchebn. Zaved., Khim. Khim. Tekhnol.*, 1998, **41**, 28. (b) For earlier work on pyrazole synthesis via nitrile imine [3 + 2] cycloadditions using ynamines, see reference 19.
22. Other methods for accessing 5-amino-iso-oxazoles: (a) M. P. Bourbeau, and J. T. Rider, *Org. Lett.*, 2006, **8**, 3679. (b) A. Alberola, A. M. Gozalez, M. A. Laguna, and F. J. Pulido, *J. Org. Chem.*, 1984, **49**, 3423. (c) E. M. Beccalli, A. Manfredi, and A. Marchesini, *J. Org. Chem.*, 1985, **50**, 2372. (d) T. Nishiwaki, and T. Saito, *J. Chem. Soc., (C)* 1971, 3021. (e) W. C. Kong, K. Kim, and Y. J. Park, *Heterocycles*, 2001, **55**, 75.
23. W. J. Close, *J. Org. Chem.*, 1950, **15**, 1131.
24. C. H. Heathcock, *Aldrichimica Acta*, 1990, **23**, 99.
25. For an excellent example of using isoxazoles as synthetic building blocks, see: (a) P. Aschwanden, L. Kvarno, R. W. Geisser, F. Kleinbeck, and E. M. Carreira, *Org. Lett.*, 2005, **7**, 5741. (b) For a review on isoxazole containing natural products, see: P. G. Barald, A. Barco, S. Benetti, G. P. Pollini, and D. Simon, *Synthesis*, 1987, 857.
26. For Lewis acidic conditions, we used: AgOTf, In(OTf)<sub>3</sub>, Zn(OTf)<sub>2</sub>, Mg(OTf)<sub>2</sub>, BF<sub>3</sub>-OEt<sub>2</sub>, and SnBr<sub>4</sub>. For Brønsted acidic conditions, we used: *p*-TsOH and Tf<sub>2</sub>NH. there are some limitations as to what Lewis or Brønsted acidic conditions we can use because they do react with ynandies. See: J. A. Mulder, K. C. M. Kurtz, R. P. Hsung, H. A. Coverdale, M. O. Frederick, L. Shen, and C. A. Zifcick, *Org. Lett.*, 2003, **5**, 1547.
27. We also tried HOAc and BF<sub>3</sub>-OEt<sub>2</sub>.
28. For examples of using pyrazoles as synthetic building blocks, see: E.-M. Chang, F.-F. Wong, T.-H. Chen, K.-C. Chiang, and M.-Y. Yeh, *Heterocycles*, 2006, **68**, 1007.